Abstract

Genomics is now a core element in the effort to develop a vaccine against HIV-1. Thanks to unprecedented progress in high-throughput genotyping and sequencing, in knowledge about genetic variation in humans, and in evolutionary genomics, it is finally possible to systematically search the genome for common genetic variants that influence the human response to HIV-1. The identification of such variants would help to determine which aspects of the response to the virus are the most promising targets for intervention. However, a key obstacle to progress remains the scarcity of appropriate human cohorts available for genomic research.

Author affiliations

1. Amalio Telenti is at the Institute of Microbiology, University Hospital, University of Lausanne, 1011 Lausanne, Switzerland.
2. David B. Goldstein is at the Institute for Genome Sciences and Policy, Center for Population Genomics and Pharmacogenetics, and the Center for HIV/AIDS Vaccine Immunology, Duke University, Durham, North Carolina 27708, USA.

Correspondence to: Amalio Telenti¹ Email: amalio.telenti@chuv.ch

Published online 9 October 2006

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.